3 European Stocks Estimated To Be Undervalued By Up To 44.8%

As European markets show signs of recovery, bolstered by the European Central Bank's interest rate cuts and a delay in higher tariffs, investors are keenly observing opportunities that may arise from these developments. In such an environment, identifying stocks that are potentially undervalued can be crucial for investors looking to capitalize on market movements while considering factors like economic policy shifts and trade uncertainties.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

Name	Current Price	Fair Value (Est)	Discount (Est)
Cenergy Holdings (ENXTBR:CENER)	€8.42	€16.49	48.9%
BFF Bank (BIT:BFF)	€7.50	€14.39	47.9%
Mips (OM:MIPS)	SEK352.60	SEK690.34	48.9%
LPP (WSE:LPP)	PLN15610.00	PLN30721.86	49.2%
Lindab International (OM:LIAB)	SEK186.80	SEK372.09	49.8%
TF Bank (OM:TFBANK)	SEK345.50	SEK683.33	49.4%
Verbio (XTRA:VBK)	€9.24	€18.25	49.4%
Stille (OM:STIL)	SEK209.00	SEK400.62	47.8%
Komplett (OB:KOMPL)	NOK11.50	NOK22.81	49.6%
Fodelia Oyj (HLSE:FODELIA)	€7.14	€13.91	48.7%

Click here to see the full list of 172 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Almirall (BME:ALM)

Overview: Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across multiple regions including Spain, Europe, the Middle East, the United States, Asia, and Africa with a market cap of approximately €2 billion.

Operations: The company's revenue segments include €97.23 million from commercial areas through licensees, €808.38 million from its own network in Europe, and €55.43 million from its own network in the United States.

Estimated Discount To Fair Value: 39%

Almirall is trading at €9.37, significantly below its estimated fair value of €15.37, suggesting it may be undervalued based on cash flows. The company's revenue is expected to grow 9.5% annually, outpacing the Spanish market's 5% growth rate, with earnings forecasted to increase by 35.8% per year over the next three years. Recent profitability and executive changes indicate a strategic focus on maintaining growth momentum in medical dermatology across Europe.

• Our comprehensive growth report raises the possibility that Almirall is poised for substantial financial growth.
• Unlock comprehensive insights into our analysis of Almirall stock in this financial health report.

Borregaard (OB:BRG)

Overview: Borregaard ASA develops, produces, and markets specialized biochemicals and biomaterials globally with a market cap of NOK16.53 billion.

Operations: The company's revenue segments consist of Bio Materials at NOK2.62 billion, Bio Solutions at NOK4.24 billion, and Fine Chemicals at NOK799 million.

Estimated Discount To Fair Value: 37.2%

Borregaard is trading at NOK 165.8, well below its estimated fair value of NOK 264.17, highlighting potential undervaluation based on cash flows. The company's earnings are forecast to grow at 14% annually, surpassing the Norwegian market's growth rate of 7.8%. Recent financial results show a year-over-year increase in fourth-quarter sales and net income, while the full-year net income slightly declined compared to the previous year.

• Our growth report here indicates Borregaard may be poised for an improving outlook.
• Click here and access our complete balance sheet health report to understand the dynamics of Borregaard.

Byggmax Group (OM:BMAX)

Overview: Byggmax Group AB (publ) operates in the sale of building materials and related products for DIY projects across Sweden, Norway, and internationally, with a market cap of SEK2.85 billion.

Operations: The company generates revenue primarily from its Byggmax segment, which accounts for SEK6.07 billion.

Estimated Discount To Fair Value: 44.8%

Byggmax Group is trading at SEK 48.65, significantly below its estimated fair value of SEK 88.15, indicating potential undervaluation based on cash flows. Earnings are projected to grow substantially at 52.24% annually over the next three years, outpacing the Swedish market's growth rate of 13.1%. Recent earnings reports show a reduction in net loss for Q1 2025 compared to the previous year, with revenue increasing from SEK 872 million to SEK 944 million year-over-year.

• Upon reviewing our latest growth report, Byggmax Group's projected financial performance appears quite optimistic.
• Delve into the full analysis health report here for a deeper understanding of Byggmax Group.

Key Takeaways

• Access the full spectrum of 172 Undervalued European Stocks Based On Cash Flows by clicking on this link.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com